Stocks Health care AVTX
NASDAQ · Health careAvalo Therapeutics, Inc. (AVTX)
It posted a net loss of $88.7M. At September 30, 2026 it held $65M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Avalo Therapeutics, Inc.
- Net worth
- Avalo Therapeutics, Inc. has a market value (market cap) of $389.9M at the latest share price, and shareholders' equity of $436.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $59K (-86.6% year on year), with a net loss of $78.3M.
- Cash flow
- In fiscal 2025 operations used $51.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Avalo Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Avalo Therapeutics, Inc. does
Avalo Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AVTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $59K | -$78.3M | -$5.84 | n/a |
| 2024 | $441K | -$35.1M | -$20.91 | -$49.1M |
| 2023 | $1.9M | -$31.5M | -$113.58 | -$30.8M |
| 2022 | $18.1M | -$41.7M | -$1,063.00 | -$26.8M |
| 2021 | $5.4M | -$84.4M | n/a | -$71M |
| 2020 | $6.7M | -$63.5M | n/a | -$40.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AVTX ranks in Health care
Latest SEC filings
What Avalo Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026
- November 5, 2026
- November 5, 2026
- November 5, 2026
- October 29, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Avalo Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.9M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 16, 2026 | Sullivan Christopher RyanChief Financial Officer | Exercised options | 12,394 | $122.5K |
| September 16, 2026 | Sullivan Christopher RyanChief Financial Officer | Soldpre-planned (10b5-1) | 12,394 | $202.4K |
| September 10, 2026 | Sullivan Christopher RyanChief Financial Officer | Exercised options | 10,185 | $81.9K |
| September 10, 2026 | Sullivan Christopher RyanChief Financial Officer | Soldpre-planned (10b5-1) | 10,185 | $179.5K |
| August 28, 2026 | Doyle MittieChief Medical Officer | Exercised options | 679 | $5.5K |
| August 28, 2026 | Doyle MittieChief Medical Officer | Soldpre-planned (10b5-1) | 679 | $13.6K |
| August 18, 2026 | Sullivan Christopher RyanChief Financial Officer | Exercised options | 31,031 | $306.6K |
| August 18, 2026 | Sullivan Christopher RyanChief Financial Officer | Soldpre-planned (10b5-1) | 31,031 | $622.3K |
Who owns AVTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 10.8% | August 7, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 9.9% | June 18, 2026 |
| TCG Crossover GP II, LLC13G, passive with 2 related filers | 7.9% | May 12, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 6.87% | August 14, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 6.3% | August 14, 2026 |
| Caligan Partners LP13G, passive with 1 related filers | 5.9% | August 14, 2026 |
| Affinity Asset Advisors, LLC13G, passive with 1 related filers | 5.5% | August 13, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 5.3% | August 14, 2026 |
| Point72 Asset Management, L.P.13G, passive with 2 related filers | 5.2% | May 26, 2026 |
| Trails Edge Capital Partners, LP13G, passive with 2 related filers | 5.2% | October 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 126 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 5,100,216 | +2,220,735 |
| BlackRock, Inc. | 4,365,553 | +4,038,471 |
| Nantahala Capital Management, LLC | 3,724,500 | +2,489,500 |
| Deep Track Capital, LP | 3,610,000 | new |
| Caligan Partners LP | 3,163,866 | +1,528,843 |
| TCG Crossover Management, LLC | 3,017,120 | +2,278,737 |
| Affinity Asset Advisors, LLC | 2,900,000 | +1,559,160 |
| State Street Corp | 2,889,287 | +2,817,633 |
| Farallon Capital Management, L.L.C. | 2,498,000 | +1,582,000 |
| Point72 Asset Management, L.P. | 2,387,026 | +1,470,884 |
| Avoro Capital Advisors LLC | 2,333,333 | +923,333 |
| Vanguard Capital Management LLC | 2,264,246 | +1,544,552 |
| Bvf Inc | 2,075,545 | +442,700 |
| Bank of America Corp | 1,913,829 | +1,270,829 |
| Adage Capital Partners GP, L.L.C. | 1,729,000 | +875,000 |
| Soleus Capital Management, L.P. | 1,654,978 | +1,213,000 |
| Braidwell LP | 1,629,182 | new |
| Alliancebernstein L.P. | 1,260,689 | new |
| UBS Group AG | 1,209,059 | +67,079 |
| Logos Global Management LP | 1,150,000 | +850,000 |
Insiders
10 insiders reported holding 376,938 shares in total, about $2.7M at the last price.
| Holder | Shares |
|---|---|
| Neil Garry ArthurChief Executive Officer, Director | 190,314 |
| Doyle MittieChief Medical Officer | 51,776 |
| Sullivan Christopher RyanChief Financial Officer | 39,900 |
| Riley JenniferChief Strategy Officer | 37,041 |
| Varki PaulChief Legal Officer | 32,576 |
| Kantoff AaronDirector | 6,333 |
| Kaplan GillaDirector | 6,333 |
| Truex SamanthaDirector | 6,333 |
| Chan MitchellDirector | 3,166 |
| Goldman JonathanDirector | 3,166 |
Questions about AVTX
What does Avalo Therapeutics, Inc. do?
Avalo Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as AVTX. Its shares trade on NASDAQ under the ticker AVTX.
What is Avalo Therapeutics, Inc.'s net worth?
Avalo Therapeutics, Inc. has a market value (market cap) of $389.9M at the latest share price, and shareholders' equity of $436.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Avalo Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $88.7M.
When did Avalo Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.
When is Avalo Therapeutics, Inc.'s next earnings report?
Avalo Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AVTX with
Follow AVTX
Get an email when Avalo Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Avalo Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.